Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton Dickinson outlines $14.30-$14.60 EPS target for FY25 amid planned biosciences separation
Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically aligned entities.
Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results
Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Becton Dickinson gains amid reports it's evaluating separating life sciences unit
Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life sciences segment.
Becton Dickinson committed to exploring all opportunities to execute separation
EST Becton Dickinson (BDX) committed to exploring all opportunities to execute separationMaximize Your Portfolio with Data Driven
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business. The company has been restructuring its business portfolio in recent years,
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors
Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.
TipRanks on MSN14h
Becton Dickinson price target raised to $269 from $265 at BofA
BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $269 from $265 and keeps a Buy rating ...
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.
Becton Dickinson (NYSE:BDX) Ticks All The Boxes When It Comes To Earnings Growth
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Becton Dickinson (NYSE:BDX). Even if this company is fairly valued by the ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Becton Dickinson (BDX), Idexx Laboratories (IDXX) and HCA Healthcare (HCA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Becton Dickinson (BDX – Research Report), Idexx Laboratories ...